BrainStorm Cell Therapeutics Data Show Treatment with NurOwn Significantly Reduces NfL, a Key Biomarker of Neurodegeneration

New data presented this week at Gordon Research Conference Analysis reinforces NfL levels as predictive of ALS clinical outcomes NEW YORK, July 7, 2023 /PRNewswire/ — BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for…